PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

PubWeight™: 4.07‹?› | Rank: Top 1%

🔗 View Article (PMID 15608678)

Published in Oncogene on February 17, 2005

Authors

Jong Woo Lee1, Young Hwa Soung, Su Young Kim, Hae Woo Lee, Won Sang Park, Suk Woo Nam, Sang Ho Kim, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee

Author Affiliations

1: Department of Pathology, College of Medicine, Catholic University of Korea, 505 Banpo-dong, Socho-gu, Seoul 137-701, Korea.

Articles citing this

(truncated to the top 100)

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72

Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99

Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90

PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87

Discovery of common Asian copy number variants using integrated high-resolution array CGH and massively parallel DNA sequencing. Nat Genet (2010) 3.49

PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42

Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15

Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04

Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell (2008) 3.02

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72

Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28

New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol (2013) 2.25

NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96

PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85

Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell (2013) 1.74

Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73

PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59

Defining the blueprint of the cancer genome. Carcinogenesis (2008) 1.49

PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer (2005) 1.48

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res (2012) 1.47

Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47

Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer (2008) 1.42

The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (2007) 1.40

Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res (2011) 1.39

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer (2012) 1.39

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle (2008) 1.35

The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33

Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol (2012) 1.31

A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes (2009) 1.29

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 1.28

LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28

Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27

Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene (2012) 1.22

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One (2011) 1.21

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica (2009) 1.21

Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res (2007) 1.21

Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med (2011) 1.21

Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A (2014) 1.20

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19

PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch (2011) 1.19

SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell (2014) 1.19

Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem (2009) 1.15

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14

PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res (2008) 1.13

Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J Transl Med (2012) 1.11

EGF-induced activation of Akt results in mTOR-dependent p70S6 kinase phosphorylation and inhibition of HC11 cell lactogenic differentiation. BMC Cell Biol (2006) 1.11

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther (2008) 1.10

mTOR signaling in tumorigenesis. Biochim Biophys Acta (2014) 1.06

Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer (2008) 1.05

The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer (2010) 1.05

BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis (2012) 1.05

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch (2008) 1.05

Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg (2009) 1.04

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res (2008) 1.02

Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer (2013) 1.02

PI3Kinase signaling in glioblastoma. J Neurooncol (2010) 1.01

Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol (2011) 0.99

Regulation of T cell homeostasis and responses by pten. Front Immunol (2012) 0.97

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res (2010) 0.97

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96

PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg (2008) 0.94

Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am (2013) 0.94

Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes. J Mol Diagn (2010) 0.94

Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer (2006) 0.93

Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget (2014) 0.93

Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS One (2011) 0.92

Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx. Diagn Pathol (2010) 0.89

Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med (2013) 0.89

Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology (2007) 0.88

Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.87

PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients. Acta Pharmacol Sin (2013) 0.86

The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets (2008) 0.86

Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. Neuro Oncol (2011) 0.86

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes (2014) 0.85

Mutational analysis of TTK gene in gastric and colorectal cancers with microsatellite instability. Cancer Res Treat (2009) 0.85

Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev (2014) 0.84

Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncol Lett (2014) 0.83

Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. Hum Genomics (2015) 0.82

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget (2016) 0.82

A pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomas. PLoS One (2015) 0.81

Anti-tumor activity of metformin: from metabolic and epigenetic perspectives. Oncotarget (2016) 0.81

DEN+2-AAF-induced multistep hepatotumorigenesis in Wistar rats: supportive evidence and insights. Protoplasma (2012) 0.80

Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome (2014) 0.80

Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. Oncol Rep (2012) 0.80

Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models. PLoS One (2013) 0.79

PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas (2014) 0.79

Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch (2016) 0.78

PIK3CA mutation in Chinese patients with lung squamous cell carcinoma. Chin J Cancer Res (2013) 0.78

Potential Role of Phosphorylation as a Regulator of Aspartyl-(asparaginyl)-β-hydroxylase: Relevance to Infiltrative Spread of Human Hepatocellular Carcinoma. Liver Cancer (2015) 0.78

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy. Toxicol Pathol (2013) 0.78

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther (2016) 0.78

Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review. BMC Cancer (2016) 0.77

Articles by these authors

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer (2009) 4.45

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68

Echocardiographic epicardial fat thickness and coronary artery disease. Circ J (2007) 2.40

Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol (2010) 2.27

Frameshift mutation of UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite instability. Hum Pathol (2008) 2.18

Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11

12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol (2010) 2.02

Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol (2003) 2.02

Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol (2009) 1.98

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res (2006) 1.98

Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res (2008) 1.90

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest (2009) 1.83

Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS (2005) 1.77

Lifetime prevalence and correlates of suicidal ideation, plan, and single and multiple attempts in a Korean nationwide study. J Nerv Ment Dis (2010) 1.75

Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73

Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion (2006) 1.73

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res (2005) 1.70

Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS (2007) 1.62

Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol (2006) 1.62

Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology (2003) 1.56

Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology (2013) 1.49

Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48

Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer (2006) 1.38

Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol (2009) 1.37

Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer (2012) 1.33

Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood (2002) 1.30

BRAF and KRAS mutations in stomach cancer. Oncogene (2003) 1.27

Genetic alterations of the KLF6 gene in gastric cancer. Oncogene (2005) 1.26

Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology (2012) 1.24

Nod1, a CARD protein, enhances pro-interleukin-1beta processing through the interaction with pro-caspase-1. Biochem Biophys Res Commun (2002) 1.23

ArrayCyGHt: a web application for analysis and visualization of array-CGH data. Bioinformatics (2005) 1.23